menu search

Amgen to buy horizon therapeutics for $116.50 per share

Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, auto...

December 12, 2022, 8:11 am

Argenx to present pivotal advance trial data during ash plenary session highlighting vyvgart® (efgartigimod alfa-fcab) as potential new treatment modality for immune thrombocytopenia

First immune thrombocytopenia (ITP) pl enary selection in 15 years underscores significant unmet need in this rare, serious ...

December 10, 2022, 11:30 am

Adding multimedia mymd pharmaceuticals® to present data on oral tnf-a inhibitor mymd-1® at the british society for immunology (bsi) congress 2022

BALTIMORE--( BUSINESS WIRE )--MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical compa...

December 6, 2022, 9:40 am

Horizon therapeutics in early takeover talks

Shares of Horizon Therapeutics surged after the biotech firm, which specializes in autoimmune diseases,...

December 1, 2022, 12:15 pm

Reasons to add immunovant (imvt) stock to your portfolio now

Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease ...

November 24, 2022, 12:47 pm

Tiziana life sciences publishes peer-reviewed research, showing intranasal administered drug for autoimmune diseases is safe in humans

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has published a scientific article in the peer-reviewed journal Frontiers in Immunology, showing a fav...

November 23, 2022, 11:41 am

Biondvax ceo to present at the january 2023 biotech showcase in san francisco

JERUSALEM , Nov. 21, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, m...

November 21, 2022, 6:00 am

Mallinckrodt will likely survive the opioid claims and litigations

Mallinckrodt develops and markets specialty pharmaceutical products for autoimmune and rare diseases. I...

November 11, 2022, 12:18 am

Argenx to present at upcoming investor conferences

November 7 , 2022 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of pe...

November 7, 2022, 1:00 am

Immunic, inc. to participate in investor conferences in september

NEW YORK , Sept. 1, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective...

September 1, 2022, 6:30 am

Argenx to present at wells fargo healthcare conference

August 31 , 2022 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peo...

August 31, 2022, 1:00 am

Aptorum group limited to present at the h.c. wainwright annual global investment conference, september 13-16, 2022

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedica...

August 25, 2022, 8:31 pm

Argenx to report half year 2022 financial results and second quarter business update on july 28, 2022

July 21, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suff...

July 21, 2022, 1:00 am

Incyte gets fda approval for a new vitiligo treatment

Incyte Corp. INCY, -1.46% said Monday that the Food and Drug Administration approved Opzelura as a topical repigmentation treatment for patients with ...

July 19, 2022, 8:33 am

Why aditxt shares are rallying today?

Aditxt Inc's (NASDAQ: ADTX) therapeutic program Adimune has completed a toxicology study indicating a favorable safety profile of ADI-100 for rejec...

July 8, 2022, 9:51 am

Immupharma hails quick response from fda for lupuzor planning meeting

Immupharma PLC said its partner in developing Lupuzor, a potential treatment for the autoimmune disease...

July 7, 2022, 3:07 am

C4x discovery nets €3mln sanofi milestone payment

Drug developer C4X Discovery Holdings PLC (AIM:C4XD) has hit the first milestone in a licensing deal with Sanofi after progressing pre-clinical trial...

July 6, 2022, 3:25 am

Pfizer (pfe) discloses autoimmune drug deal with priovant

Pfizer (PFE) announces the name of the new company that it formed with its partner, Roivant Sciences (ROIV), to develop and market its dual TYK2/JAK1 ...

June 29, 2022, 12:24 pm

Roivant, pfizer unveil priovant therapeutics focused on autoimmune disease treatments, roivant stock surges

Shares of Roivant Sciences Ltd. ROIV, -2.30% shot up 10.0% in premarket trading Tuesday, after the biopharmaceutical company and drug giant Pfizer Inc...

June 28, 2022, 6:27 am

Immupharma lupus treatment on final stage of process for new clinical trial

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) said partner Avion Pharmaceuticals has moved to the final stage of the US regulatory process ahead of a new phase ...

June 27, 2022, 3:12 am


Search within

Pages Search Results: